Plain Language Summary of a Phase 2b Randomized Controlled Trial of Ecopipam and Its 12-Month Open-Label Extension in Children and Adolescents With Tourette Syndrome

Therapeutic Advances in Neurological Disorders 2026 Open access

Read full text
Authors: Donald L. Gilbert, David J.B. Kim, Meredith M. Miller, Sarah D. Atkinson, George B. Karkanias, Frederick E. Munschauer, Stephen P. Wanaski, Timothy M. Cunniff
DOI: 10.1177/17562864261424987
Cited by: 0

Abstract

What is this summary about? The purpose of this summary is to explain the results from two studies that looked at the safety and effects of an investigational drug called ecopipam. "Investigational" means that the drug has not been approved by the United States Food and Drug Administration (FDA) yet. The studies tested if ecopipam could safely improve symptoms and quality of life in children and adolescents with Tourette syndrome. Please note that ecopipam is not currently approved to treat Tourette syndrome.

Fields of Study & Subjects

Obsessive-Compulsive Spectrum Disorders Stuttering Research and Treatment Schizophrenia research and treatment

Publication details

Journal / source
Therapeutic Advances in Neurological Disorders
Volume
19
Pages
17562864261424987–17562864261424987
Publication date
26 February 2026
Language
EN